Drug Profile
GL 48656
Alternative Names: GL-48656Latest Information Update: 04 Mar 2008
Price :
$50
*
At a glance
- Originator Genelabs Technologies
- Class Antifungals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Aspergillosis
Most Recent Events
- 26 Sep 2003 Data presented at the 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the Bacterial infections antimicrobial activity and pharmacodynamics section ,,
- 16 Sep 2003 GL 48656 is available for licensing (http://genelabs.com)
- 26 Mar 2003 Preclinical trials in Aspergillosis in USA (unspecified route)